 [21] 
  The essence of the Defendants' arguments is that Apotex's pleadings with respect to SPIL must be struck because the allegations of material fact are speculative, particularly with respect to SPIL's control over Roche and their common enterprise. The Defendants further argue that Apotex is abusing the process of the Court by pleading facts based on speculation in the hopes of finding a true basis of a cause of action at discovery. 
